Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non–small-cell lung cancer (NSCLC): LEAP-006.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: The University of Sydney, Westmead Hospital, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, German Center for Lung Research, LungenClinic Grosshansdorf, Hospital Universitario Insular de Gran Canaria, Eisai (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), Yale Cancer Center, Yale University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2947529692